Radiopharm Theranostics Limited ADR (RADX)
NASDAQ: RADXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RADX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.90M
- EPS (TTM)
- -$3.64
- Dividend yield
- None
- 52-week range
- 0.63 – 16.25
- Day range
- 0.63 – 0.716
- Volume / Avg
- 12.98K / 55.23K
- Beta
- —
- Shares outstanding
- 15.70M
52-week range
RADX stock today
On Nov 20, RADX ended the session at $0.6304, shedding $0.0678 (9.71%), versus the S&P 500's 3.70% decline. Trading was light, with 12.98K shares changing hands, about 24% of the average daily volume. Shares are 96.1% below their 52-week high of $16.25, set on Dec 15, 2025 and 0.1% above the 52-week low of $0.63, near the bottom of the past year's range.
RADX is down 87.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 86.1%. Radiopharm Theranostics has posted a net loss over the last twelve months (EPS of -$3.64), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Radiopharm Theranostics
Company profileRadiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Riccardo Canevari
- Headquarters
- Carlton, VIC
- Employees
- 14
- Website
- radiopharmtheranostics.com
Financial highlights
Full financialsIn fiscal 2025, Radiopharm Theranostics generated $3.6 million in revenue, up 1114.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Radiopharm Theranostics reported a net loss of $38.3 million, compared with a loss of $47.9 million a year earlier. Gross margin was 1.1% (down from 100.0%) and operating margin -1050.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $3.63M | $299.23K | $292.36K |
| Growth | +1114.27% | +2.35% | — |
| Net income | $-38.34M | $-47.95M | $-34.61M |
| EPS (diluted) | $-1.76 | $-12.41 | $-11.32 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$16.99+2595.11%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
RADX news
All RADX news- Radiopharm Theranostics Limited - Depositary Receipt Price Target Increased by 10.97% to $14.67Nasdaq
- Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain MetastasesGlobeNewswire
- Radiopharm Aligns With FDA On Single Pivotal Phase 3 RAD101 Trial For Brain MetastasesNasdaqRADX, HEI.A
- Radiopharm Theranostics Reports Business UpdateGlobeNewswire
- GE HealthCare Wins Approval for MINItrace Magni Cyclotron in EuropeNasdaqGEHC, LNTH, TLX, RADX
Radiopharm Theranostics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ASBPAspire-Lakewood Holdings Inc. | 7.13 | -5.44% | $10.00M | vs RADX |
| CMMBChemomab Therapeutics Ltd. ADR | 1.19 | +4.39% | $9.58M | vs RADX |
| BFRIBiofrontera Inc. | 0.53 | -7.02% | $9.51M | vs RADX |
| AEONAEON Biopharma Inc. Class A | 0.123 | -7.59% | $10.35M | vs RADX |
| GDTCCytoMed Therapeutics Limited | 0.755 | -2.33% | $9.01M | vs RADX |
| CALCCalciMedica Inc. | 1.26 | +7.69% | $8.69M | vs RADX |
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs RADX |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs RADX |
Indexes, lists and sector
Radiopharm Theranostics stock FAQ
What is Radiopharm Theranostics's stock price today?
RADX last traded at $0.6304 as of Nov 20, 4:00 PM EST, down 9.71% on the day. Prices are delayed at least 15 minutes.
Who is Radiopharm Theranostics's CEO?
Mr. Riccardo Canevari is the chief executive officer of Radiopharm Theranostics Limited ADR, which has about 14 employees.
What is the RADX 52-week high?
The 52-week high for RADX is $16.25 and the 52-week low is $0.63. The stock is currently 96.1% below its high.